Gene Therapeutic Vector for KSHV-Associated Diseases

Abstract

Researchers at the University of California, Davis have developed a gene therapy that selectively targets KSHV-infected tumors through virus-specific sequences and suicide genes to induce tumor cell death.

Full Description

This technology involves the creation of gene therapy vectors, such as adeno-associated virus (AAV) vectors, which incorporate Kaposi's sarcoma-associated herpesvirus (KSHV) terminal repeat (TR) sequences and suicide genes to specifically target and eliminate KSHV-infected tumor cells. The TR sequences enhance the expression of therapeutic genes, leading to the apoptosis of tumor cells without affecting non-infected cells.

Applications

• Gene therapy products for treating Kaposi’s sarcoma and other KSHV-related tumors. 
• Combination therapieswith existing cancer drugs to enhance therapeutic efficacy. 
• Diagnostic tools for identifying KSHV-infected cells.

Features/Benefits

• High specificity for KSHV-infected tumor cells, minimizing damage to healthy cells. 
• Utilizes the virus's own regulatory mechanisms to enhance the therapeutic effectiveness. 
• Potential for combination with other treatments to further improve outcomes. 
• Flexible platform allowing for the incorporation of various suicide genes. 
• Provides effective therapies for KSHV-associated malignancies. 
• Reduces high mortality rates linked to diseases like primary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD). 
• Overcomes challenges in selectively targeting infected cells, sparing healthy tissues.

Patent Status

Patent Pending